Delivery Order SPE2DB22D2211-SPE2DB25FSECV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,256.92 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price, competitively awarded contract represents a small-value pharmaceutical delivery with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,636.67. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Jatenzo 237 mg capsules (120 count) with a ceiling value of $2,263.74. This is a firm fixed-price contract with an ultimate completion date of September 18, 2025. The award was competitively made with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a...
- The Department of Defense's Medical Supply Chain awarded a $4,267.48 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,283.72 to AmerisourceBergen Drug Corp for Jatenzo 237 mg capsules (120-count supply) on September 9, 2025, with completion scheduled for September 10, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $5,877.30 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on August 20, 2025, with completion scheduled for August 21, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg, valued at $1,142.26, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $2,137.63 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg, a testosterone replacement therapy medication. This non-set-aside, competitively awarded contract was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and operates under a firm fixed price arrangement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $1,131.88 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jatenzo 158 mg capsules (120-count unit). This firm fixed-price delivery order, which is a child contract under a larger vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. The award utilized no set-aside designation and was competitively awarded through open...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSECVDelivery Order
The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $3,347.66 for Jatenzo 198 mg capsules (120-count units) with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products to military and veteran healthcare systems through the DLA. The company's contract portfolio demonstrates extensive experience fulfilling federal medical procurement needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and vaccines. This delivery order for Jatenzo, a testosterone replacement therapy medication, exemplifies the company's role in supporting Defense Health Agency operations and broader military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 9/3/25 |